A NAD precursor is a compound that the body can convert into nicotinamide adenine dinucleotide, a molecule that takes part in many metabolic reactions. In Unfair, NAD precursor is treated as a category label for tracking purposes, not as a youth pill. The two best-known members are NMN and NR, and both are studied as research compounds rather than proven human longevity interventions.
What the category means
The category includes molecules used to study NAD-related markers in animal research and limited human work. The relevant evidence tier for human clinical outcomes remains low. NAD precursors should not be described as proven longevity interventions, and individual users should not expect rejuvenation from any single product.
The mechanism of action story for NAD precursors is interesting at the cellular level. That is not the same as proof that taking a capsule daily changes how a person ages.
How they sit in a stack
In a supplement stack, an NAD precursor is one optional line with a defined dose, a dose window, and a review block. The pillar building your first supplement stack applies here, because adding NAD precursors on top of a busy stack tends to break review attribution: too many new items at once and no item can be judged.
The user should decide what they would actually measure across the block: energy ratings, training proxies, sleep, or specific labs. If the answer is nothing, the item is unlikely to earn its place.
Limits of the claim
A NAD precursor product does not rejuvenate humans, does not guarantee a change in healthspan, and does not replace exercise, sleep, or medical care. Marketing language that suggests otherwise should be discounted heavily.
NAD precursor products vary in identity, purity, dose, and pricing. Cost per day across a year matters when the readable benefit in a personal review may be small or absent.
How this appears in Unfair
In Unfair, an NAD precursor appears as a tracked item with conservative claims, a defined review block, and a stop rule. Linked library entries describe each compound; the glossary entry stays at the category level.
Clinical safety note
Medication use, cancer history, pregnancy, and other medical contexts move NAD-precursor questions into clinician review rather than app-only stack tuning.